Pharmacologic management of drug-resistant genitourinary tumors

Michael W. DeGregorio, Valerie J. Wiebe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The purpose of this article is to examine potentially useful treatment strategies for drug-resistant genitourinary (GU) tumors. To achieve the desired pharmacologic effect, adequate concentration vs time (C×T) drug kinetic profiles must be achieved at the target tissues. Inadequate C×T drug profiles can result from low vascular tissues, rapid drug metabolism, and insufficient dosing schedules. These factors may also contribute to the development of acquired drug resistance by enabling tumor cells to repair sublethal damage caused by cytotoxic drugs. Although the development of acquired drug resistance may represent a normal response to foreign agents and hence be inevitable in many tumors, dose-intensive regimens as first-line treatment may delay the clinical onset of resistance. Once acquired drug resistance does develop, several investigational treatment strategies aimed at biochemical mechanisms of resistance may further circumvent treatment failures. Finally, intrinsic drug resistance represents an additional problem in certain GU tumors, particularly renal cell carcinoma. In this case, dose-intensive treatment regimens that incorporate a chemosensitizing agent may prove to the useful as firstline therapy. Tumor-specific treatment regimens need to be developed based on many factors, including degree of intrinsic resistance, past chemotherapy, stage and site of disease, and patient tolerance to aggressive treatment regimens.

Original languageEnglish (US)
Pages (from-to)6-12
Number of pages7
JournalWorld Journal of Urology
Volume8
Issue number1
DOIs
StatePublished - Mar 1990
Externally publishedYes

Fingerprint

Drug Resistance
Pharmaceutical Preparations
Neoplasms
Therapeutics
Investigational Therapies
Treatment Failure
Renal Cell Carcinoma
Blood Vessels
Appointments and Schedules
Pharmacokinetics
Drug Therapy

ASJC Scopus subject areas

  • Urology

Cite this

Pharmacologic management of drug-resistant genitourinary tumors. / DeGregorio, Michael W.; Wiebe, Valerie J.

In: World Journal of Urology, Vol. 8, No. 1, 03.1990, p. 6-12.

Research output: Contribution to journalArticle

DeGregorio, Michael W. ; Wiebe, Valerie J. / Pharmacologic management of drug-resistant genitourinary tumors. In: World Journal of Urology. 1990 ; Vol. 8, No. 1. pp. 6-12.
@article{11cacee1521a4a5f93e8a8b9db5a20e2,
title = "Pharmacologic management of drug-resistant genitourinary tumors",
abstract = "The purpose of this article is to examine potentially useful treatment strategies for drug-resistant genitourinary (GU) tumors. To achieve the desired pharmacologic effect, adequate concentration vs time (C×T) drug kinetic profiles must be achieved at the target tissues. Inadequate C×T drug profiles can result from low vascular tissues, rapid drug metabolism, and insufficient dosing schedules. These factors may also contribute to the development of acquired drug resistance by enabling tumor cells to repair sublethal damage caused by cytotoxic drugs. Although the development of acquired drug resistance may represent a normal response to foreign agents and hence be inevitable in many tumors, dose-intensive regimens as first-line treatment may delay the clinical onset of resistance. Once acquired drug resistance does develop, several investigational treatment strategies aimed at biochemical mechanisms of resistance may further circumvent treatment failures. Finally, intrinsic drug resistance represents an additional problem in certain GU tumors, particularly renal cell carcinoma. In this case, dose-intensive treatment regimens that incorporate a chemosensitizing agent may prove to the useful as firstline therapy. Tumor-specific treatment regimens need to be developed based on many factors, including degree of intrinsic resistance, past chemotherapy, stage and site of disease, and patient tolerance to aggressive treatment regimens.",
author = "DeGregorio, {Michael W.} and Wiebe, {Valerie J.}",
year = "1990",
month = "3",
doi = "10.1007/BF01576271",
language = "English (US)",
volume = "8",
pages = "6--12",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Pharmacologic management of drug-resistant genitourinary tumors

AU - DeGregorio, Michael W.

AU - Wiebe, Valerie J.

PY - 1990/3

Y1 - 1990/3

N2 - The purpose of this article is to examine potentially useful treatment strategies for drug-resistant genitourinary (GU) tumors. To achieve the desired pharmacologic effect, adequate concentration vs time (C×T) drug kinetic profiles must be achieved at the target tissues. Inadequate C×T drug profiles can result from low vascular tissues, rapid drug metabolism, and insufficient dosing schedules. These factors may also contribute to the development of acquired drug resistance by enabling tumor cells to repair sublethal damage caused by cytotoxic drugs. Although the development of acquired drug resistance may represent a normal response to foreign agents and hence be inevitable in many tumors, dose-intensive regimens as first-line treatment may delay the clinical onset of resistance. Once acquired drug resistance does develop, several investigational treatment strategies aimed at biochemical mechanisms of resistance may further circumvent treatment failures. Finally, intrinsic drug resistance represents an additional problem in certain GU tumors, particularly renal cell carcinoma. In this case, dose-intensive treatment regimens that incorporate a chemosensitizing agent may prove to the useful as firstline therapy. Tumor-specific treatment regimens need to be developed based on many factors, including degree of intrinsic resistance, past chemotherapy, stage and site of disease, and patient tolerance to aggressive treatment regimens.

AB - The purpose of this article is to examine potentially useful treatment strategies for drug-resistant genitourinary (GU) tumors. To achieve the desired pharmacologic effect, adequate concentration vs time (C×T) drug kinetic profiles must be achieved at the target tissues. Inadequate C×T drug profiles can result from low vascular tissues, rapid drug metabolism, and insufficient dosing schedules. These factors may also contribute to the development of acquired drug resistance by enabling tumor cells to repair sublethal damage caused by cytotoxic drugs. Although the development of acquired drug resistance may represent a normal response to foreign agents and hence be inevitable in many tumors, dose-intensive regimens as first-line treatment may delay the clinical onset of resistance. Once acquired drug resistance does develop, several investigational treatment strategies aimed at biochemical mechanisms of resistance may further circumvent treatment failures. Finally, intrinsic drug resistance represents an additional problem in certain GU tumors, particularly renal cell carcinoma. In this case, dose-intensive treatment regimens that incorporate a chemosensitizing agent may prove to the useful as firstline therapy. Tumor-specific treatment regimens need to be developed based on many factors, including degree of intrinsic resistance, past chemotherapy, stage and site of disease, and patient tolerance to aggressive treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0025293817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025293817&partnerID=8YFLogxK

U2 - 10.1007/BF01576271

DO - 10.1007/BF01576271

M3 - Article

AN - SCOPUS:0025293817

VL - 8

SP - 6

EP - 12

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 1

ER -